MktsMarkets

IN8bio, Inc.
NASDAQ: INABKey statistics
INAB News
Stories mentioning INAB from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 2,613 | 2,648 | 2,104 | 2,487 | 2,972 | 3,594 | 3,309 | 5,156 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 5,266 | 5,033 | 3,967 | 5,201 | 5,660 | 6,224 | 7,109 | 8,689 |
| Operating Income (Loss) | (5,090) | (4,942) | (3,854) | (5,094) | (5,550) | (6,160) | (7,086) | (8,629) |
| Interest Income | 176.00 | 91.00 | 113.00 | 107.00 | 110.00 | 64.00 | 23.00 | 60.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (5,090) | (4,942) | (3,854) | (5,094) | (5,550) | (6,160) | (7,086) | (8,629) |
| Earnings Per Share (Basic) | (0.26) | (1.13) | (0.85) | (1.24) | (2.16) | (3.45) | (4.49) | (5.51) |
| Earnings Per Share (Diluted) | (0.26) | (1.13) | (0.85) | (1.24) | (2.16) | (3.45) | (4.49) | (5.51) |
| Weighted Average Shares Outstanding (Basic) | 19,467 | 4,374 | 4,538 | 4,119 | 2,575 | 1,785 | 1,577 | 1,567 |
| Weighted Average Shares Outstanding (Diluted) | 19,467 | 4,374 | 4,538 | 4,119 | 2,575 | 1,785 | 1,577 | 1,567 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About INAB
IN8bio, Inc. (NASDAQ: INAB) is a stock listed on the Nasdaq Stock Market under the ticker symbol INAB. It last traded at $0.9300 (Nov 4, 2026, 9:30 AM ET), down 2.0% on the day. That gives IN8bio a market capitalisation of $8.9M.
Over the past 52 weeks INAB has traded between $0.8700 and $2.73.
For the quarter ended Mar 31, 2026 it reported a net loss of $5.1M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$5.1M |
| Dec 31, 2025 | — | -$4.9M |
| Sep 30, 2025 | — | -$3.9M |
| Jun 30, 2025 | — | -$5.1M |
From IN8bio’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…